ASCENTAGE (06855.HK): Interim Revenue Up 29.3% to RMB 302.2 Million, Net Loss Widens to RMB 817.0 Million

NewTimeSpace News: On 17 September 2026, Ascentage Pharma Group International (stock code: 06855) published its 2026 interim report. Revenue for the six months ended 30 June 2026 was RMB 302.2 million, up 29.3% year on year on a constant exchange rate basis, driven by a 32.6% increase in product sales to RMB 282.4 million. Net loss for the period was RMB 817.0 million, compared with a loss of RMB 590.8 million a year earlier, and basic and diluted loss per share was RMB 2.19.

Total operating expenses rose 36.1% to RMB 1,042.7 million, of which research and development expenses increased 32.0% to RMB 697.5 million, mainly due to progress in the Group's ongoing global clinical trials, while selling and distribution expenses rose 64.3% to RMB 226.4 million, mainly attributable to increased marketing and promotion investment in Lisaftoclax.

As at 30 June 2026, the Group's cash and bank balances were RMB 1,895.6 million, down 23.3% from 31 December 2025, mainly due to ongoing operating expenses related to global clinical trials and research and development. No fundraising activities were carried out during the reporting period; the current ratio fell to 1.2 from 1.8 and the gearing ratio rose to 35.8%.

With effect from 1 June 2026, the Company removed the "B" marker from its Chinese and English stock short names, having met the market capitalisation/revenue test under Rule 8.05(3) of the Listing Rules and been granted relief from Rules 18A.09 to 18A.11. Its BTK-targeted protein degrader APG-3288 obtained investigational new drug clearance from the US FDA in January 2026 and from the CDE of China's National Medical Products Administration in February 2026, and a Phase I study in relapsed or refractory haematological malignancies is under way; on 3 August 2026, the Company appointed Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.